Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Tax Provisions (2017 - 2025)

Vanda Pharmaceuticals' Tax Provisions history spans 11 years, with the latest figure at $103.2 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 6468.11% to $103.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $81.8 million, a 2126.32% increase, with the full-year FY2025 number at $81.8 million, up 2134.99% from a year prior.
  • Tax Provisions hit $103.2 million in Q4 2025 for Vanda Pharmaceuticals, up from -$5.8 million in the prior quarter.
  • Over the last five years, Tax Provisions for VNDA hit a ceiling of $103.2 million in Q4 2025 and a floor of -$7.9 million in Q1 2025.
  • Historically, Tax Provisions has averaged $4.8 million across 5 years, with a median of $919500.0 in 2023.
  • The widest YoY moves for Tax Provisions: up 6468.11% in 2025, down 1425.1% in 2025.
  • Tracing VNDA's Tax Provisions over 5 years: stood at $1.5 million in 2021, then skyrocketed by 82.01% to $2.8 million in 2022, then plummeted by 73.15% to $739000.0 in 2023, then plummeted by 319.35% to -$1.6 million in 2024, then surged by 6468.11% to $103.2 million in 2025.
  • Business Quant data shows Tax Provisions for VNDA at $103.2 million in Q4 2025, -$5.8 million in Q3 2025, and -$7.7 million in Q2 2025.